Combination of two targeted drugs for resistant FLT3-mutated AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of two targeted drugs, SNDX-5613 and gilteritinib, for people whose AML has come back or hasn't responded to treatment. It is for those with an FLT3 gene mutation plus another specific genetic change like NPM1 or MLL. The study aims to see if this two-drug approach works better when used together.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of AML called FLT3-mutated (either ITD or TKD), and also another gene change such as NPM1 mutation or MLL rearrangement.
- Your leukemia has not responded to at least 2 cycles of standard treatment or has come back after treatment.
- You are currently taking one of these antifungals: itraconazole, ketoconazole, posaconazole, or voriconazole (for at least 24 hours before starting the study).
- You are not able to receive intensive chemotherapy right now (due to age, other health issues, or hospital policy).
- Your overall health is fairly good (ECOG score 0–2) and your kidney, liver, and heart function are within the study limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three medicines—azacitidine, venetoclax, and gilteritinib—in people with specific gene changes (FLT3 mutations) in leukemia and related bone marrow diseases that have come back or are hard to treat. The goal is to see if this drug combination can control the disease and improve outcomes.
This early-phase study tests a menin inhibitor drug (SNDX-5613) combined with standard induction chemotherapy (daunorubicin plus cytarabine) in newly diagnosed AML with specific gene changes (NPM1 or FLT3 status, or MLL/KMT2A or NUP98). It may help patients whose AML has these genetic features respond better to intensive treatment.
This Phase 1/2 trial tests a combination of medicines (ASTX727, venetoclax, and gilteritinib) for adults with FLT3-mutated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It aims to see how well the treatment works and how safe it is for people whose disease has come back, is not responding, or (for some) is newly diagnosed.
This study tests a combination of two targeted drugs, gilteritinib and momelotinib, for people whose acute myeloid leukemia (AML) has returned or has not responded to standard treatment. The drugs aim to block signals that help leukemia cells grow, potentially offering a new option for those with a FLT3 mutation.
This trial compares a new combination treatment to standard chemotherapy plus a targeted drug (called an FLT3 inhibitor) in people with AML that has a FLT3 mutation. The goal is to see if the new approach works better and helps improve outcomes.
This trial tests a three-drug combination for people with acute myeloid leukemia (AML) that did not respond to or came back after previous treatment with azacitidine and venetoclax. The goal is to see if adding gilteritinib can help control the leukemia.
Hear when a new Acute Myeloid Leukemia With FLT3/ITD Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.